Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clemens-Martin Wendtner

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Blood|May 9, 2015
Targeted drugs in concert with chemo: opposites attractClemens-Martin Wendtner, Kirsten Fischer
Deutsche Medizinische Wochenschrift (1946)|April 1, 2015
[Chronic lymphatic leukemia]Manuela Bergmann, Clemens-Martin Wendtner
Leukemia & Lymphoma|June 2, 2017
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemiaClemens-Martin Wendtner, Michael Gregor
Oncotargets and Therapy|July 10, 2010
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumabCarmen Diana Schweighofer, Clemens-Martin Wendtner
Leukemia & Lymphoma|November 29, 2024
Clinical trials in early-stage CLL: what has been learned and what's next?Manuela A Hoechstetter, Clemens-Martin Wendtner
Leukemia & Lymphoma|April 7, 2009
Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemiaChristian Philipp Pallasch, Clemens Martin Wendtner
Current Hematologic Malignancy Reports|April 29, 2010
Use of alemtuzumab and rituximab consolidation in CLL: Pros and consThomas Elter, Barbara F Eichhorst, Clemens-Martin Wendtner
Leukemia & Lymphoma|August 7, 2010
Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAsMichaela Patz, Christian P Pallasch, Clemens-Martin Wendtner
Onkologie|January 31, 2012
Targeted therapy of soft tissue sarcomasEva Wardelmann, Jens M Chemnitz, Clemens-Martin Wendtner
Current Hematologic Malignancy Reports|April 29, 2010
Eradication of minimal residual disease in chronic lymphocytic leukemiaCarmen Diana Schweighofer, Michael Hallek, Clemens-Martin Wendtner
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Blood|May 9, 2015
Targeted drugs in concert with chemo: opposites attractClemens-Martin Wendtner, Kirsten Fischer
Deutsche Medizinische Wochenschrift (1946)|April 1, 2015
[Chronic lymphatic leukemia]Manuela Bergmann, Clemens-Martin Wendtner
Leukemia & Lymphoma|June 2, 2017
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemiaClemens-Martin Wendtner, Michael Gregor
Oncotargets and Therapy|July 10, 2010
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumabCarmen Diana Schweighofer, Clemens-Martin Wendtner
Leukemia & Lymphoma|November 29, 2024
Clinical trials in early-stage CLL: what has been learned and what's next?Manuela A Hoechstetter, Clemens-Martin Wendtner
Leukemia & Lymphoma|April 7, 2009
Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemiaChristian Philipp Pallasch, Clemens Martin Wendtner
Current Hematologic Malignancy Reports|April 29, 2010
Use of alemtuzumab and rituximab consolidation in CLL: Pros and consThomas Elter, Barbara F Eichhorst, Clemens-Martin Wendtner
Leukemia & Lymphoma|August 7, 2010
Critical role of microRNAs in chronic lymphocytic leukemia: overexpression of the oncogene PLAG1 by deregulated miRNAsMichaela Patz, Christian P Pallasch, Clemens-Martin Wendtner
Onkologie|January 31, 2012
Targeted therapy of soft tissue sarcomasEva Wardelmann, Jens M Chemnitz, Clemens-Martin Wendtner
Current Hematologic Malignancy Reports|April 29, 2010
Eradication of minimal residual disease in chronic lymphocytic leukemiaCarmen Diana Schweighofer, Michael Hallek, Clemens-Martin Wendtner
Pageof 11